| Q37301641 | A survey of Canadian urologists' opinions and prescribing patterns of testosterone replacement therapy in men on active surveillance for low-risk prostate cancer |
| Q41259705 | Addressing the pressing issues related to testosterone administration to men with prostate cancer |
| Q37836264 | Androgen regulation of prostate cancer: where are we now? |
| Q42908268 | Androgen replacement therapy after prostate cancer treatment |
| Q42537805 | Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer |
| Q57828021 | Benefits and Consequences of Testosterone Replacement Therapy: A Review |
| Q26773738 | Challenges to treat hypogonadism in prostate cancer patients: implications for endocrinologists, urologists and radiotherapists |
| Q34293663 | Current state of practice regarding testosterone supplementation therapy in men with prostate cancer |
| Q36293061 | Diagnosis and management of testosterone deficiency |
| Q37868755 | Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry |
| Q45351575 | Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer |
| Q33976165 | Off-label use of hormones as an antiaging strategy: a review |
| Q91806154 | Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis |
| Q38383552 | Recurrence of prostate cancer in patients receiving testosterone supplementation for hypogonadism |
| Q37165019 | Risks and benefits of late onset hypogonadism treatment: an expert opinion |
| Q38155496 | Serum testosterone level, testosterone replacement treatment, and prostate cancer |
| Q42932119 | Should Hypogonadal Men With Prostate Cancer Receive Testosterone? |
| Q26771774 | Testosterone Replacement Therapy and Prostate Cancer Incidence |
| Q38913362 | Testosterone Therapy Among Prostate Cancer Survivors. |
| Q38822102 | Testosterone Therapy and Prostate Cancer |
| Q38683604 | Testosterone Therapy in Men With Prostate Cancer |
| Q38739186 | Testosterone Therapy on Active Surveillance and Following Definitive Treatment for Prostate Cancer |
| Q26770414 | Testosterone deficiency in the aging male |
| Q38037508 | Testosterone replacement and prostate cancer. |
| Q94683810 | Testosterone replacement therapy (TRT) and prostate cancer: An updated systematic review with a focus on previous or active localized prostate cancer |
| Q26823279 | Testosterone replacement therapy and the risk of prostate cancer |
| Q28285210 | Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy |
| Q38042783 | Testosterone replacement therapy in the setting of prostate cancer treated with radiation |
| Q37531045 | Testosterone therapy and prostate cancer |
| Q43594011 | Testosterone therapy and prostate cancer--safety concerns are well founded |
| Q35009920 | Testosterone therapy and prostate carcinoma |
| Q57105836 | Testosterone therapy for high-risk prostate cancer survivors: a systematic review and meta-analysis |
| Q36293127 | Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations |
| Q57110809 | The Role of Testosterone Therapy in the Setting of Prostate Cancer |
| Q38234728 | The safety of testosterone supplementation therapy in prostate cancer |
| Q38212063 | To treat or not to treat with testosterone replacement therapy: a contemporary review of management of late-onset hypogonadism and critical issues related to prostate cancer |
| Q37848698 | Use of testosterone replacement therapy in patients with prostate cancer |